Dr. Bakouny on Understanding the Biology of Translocation RCC

Video

Ziad Bakouny, MD, MSc, discusses understanding the biology of translocation renal cell carcinoma.

Ziad Bakouny, MD, MSc, internal medicine resident, Brigham and Women’s Hospital, Harvard Medical School,discusses understanding the biology of translocation renal cell carcinoma (tRCC).

It is important to understand the biology of tRCC for many reasons, Bakouny says. This disease is aggressive and the patients it affects typically have poor outcomes, Bakouny explains. Moreover, tRCC disproportionately affects young patients​, particularly young women; therefore, tRCC confers a significant disease burden for this patient population, Bakouny says.

Overall, if the biology of this disease does not become more widely understood, it will not be possible to target it with effective treatment, Bakouny continues. Currently, extrapolation from data in other disease subtypes, such as clear cell RCC, has not yielded optimal insight into treating patients with tRCC, Bakouny says. Therefore, research is needed to understand the biology of tRCC, target the disease, and improve outcomes for patients, Bakouny conclude.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine